Celtaxsys has completed its Phase 2b trial assessing the safety and effectiveness of acebilustat (formerly CTX-4430 ) for CF, with the company announcing the last visit of the last enrolled patient.

Details of the trial, supported by the Cystic Fibrosis Foundation, will be presented at the upcoming 41st European Cystic Fibrosis Society Conference June 6-9 in Belgrade, Serbia, in an oral presentation titled “Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF).”

The company expects to release clinical trial results in July.

“Completing this trial represents a significant milestone for the development of our lead medicine, the company and the CF community. We are excited to explore once daily acebilustat’s potential to reduce excessive lung inflammation as a complement to a CF patient’s current treatment regimen, irrespective of genotype,” Greg Duncan, president and CEO of Celtaxsys, said in a press release.